Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Recruiting now · Phase 3

Conditions studied: IBS - Irritable Bowel Syndrome

In brief

Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome

Key facts

Study ID

NCT04217733

Run by

Tanta University

People needed

60

Starts

2019-11-01

Expected to finish

2030-12-30

Last updated by the study team

2020-01-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Age ≥ 18 years,
• Man and Women, Negative pregnancy test and effective contraception,
• IBS defined by the Rome criteria IV
• During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.
• IBS Treatment stable for 1 month

You may not qualify if…

• • Breastfeeding
• Diabetic patients
• Significant liver function abnormalities (transaminases> 3N, cholestasis) and moderate renal disease (MDRD <60 ml / min)
• Addiction to alcohol and / or drugs,
• Antiepileptic drugs taken (epilepsy or chronic pain)
• Chronic pain of greater intensity than that related to IBS,
• Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline.
• History or current severe depression (hospitalization, long-term antidepressant treatment)
• Psychotic disorders,

Where it is running

• Sherief Abd-Elsalam — Tanta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.